SILBERSHER v. JANSSEN BIOTECH INC.

CourtDistrict Court, D. New Jersey
DecidedJanuary 26, 2022
Docket2:19-cv-12107
StatusUnknown

This text of SILBERSHER v. JANSSEN BIOTECH INC. (SILBERSHER v. JANSSEN BIOTECH INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SILBERSHER v. JANSSEN BIOTECH INC., (D.N.J. 2022).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

UNITED STATES OF AMERICA, STATES OF CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, FLORIDA, GEORGIA, HAWAII, ILLINOIS, INDIANA, IOWA, LOUISIANA, MICHIGAN, MINNESOTA, MONTANA, NEVADA, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, OKLAHOMA, RHODE ISLAND, TENNESSEE, TEXAS, VERMONT, AND WASHINGTON; THE COMMONWEALTHS OF Civ. No. 19-12107 (KM) (ESK) MASSACHUSETTS AND VIRGINIA; AND THE DISTRICT OF COLUMBIA, OPINION & ORDER ex rel. ZACHARY SILBERSHER, Plaintiffs, v. JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, and JOHNSON & JOHNSON, Defendants.

KEVIN MCNULTY, U.S.D.J.: On June 20, 2019, Plaintiff Zachary Silbersher, as relator, filed the operative Second Amended Complaint alleging claims for violations of the False Claims Act (“FCA”), 31 U.S.C. §§ 3729-3733, and numerous state laws against Defendants Johnson & Johnson (“J&J”) and subsidiaries Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC, in connection with their acquisition of a patent covering the pharmaceutical drug Zytiga. (DE 63.)1 On December 17, 2021, I denied Defendants’ motion to dismiss as to J&J and its subsidiaries.2 (DE 180) Defendants now move, pursuant to 28 U.S.C. § 1292(b), to certify an interlocutory appeal on the question of whether information disclosed in inter partes review (“IPR”) proceedings or on the Patent and Trade Office’s (“PTO”) PAIR database triggers the FCA’s public disclosure bar.3 (Defs. Mot. at 1-2, 7.) Additionally, Defendants move for a stay pending appeal. (Id. at 1, 19.) For the following reasons, the motion is DENIED. I. BACKGROUND I assume familiarity with the factual background and procedural history of the instant dispute as set forth in my prior opinion denying, in part, Defendants’ motion to dismiss. (See DE 179 at 2-9.) In that opinion, I rejected Defendants’ argument that the substance of Plaintiff’s allegations was publicly disclosed in one of the three enumerated channels triggering the FCA’s public disclosure bar.4 Specifically, I concluded that IPR proceedings did not

1 Certain citations to the record are abbreviated as follows: DE refers to the docket entry numbers in this case. Defs. Mot. refers to Defendants’ Memorandum in Support of Defendants’ Motion to Certify Interlocutory Appeal and for a Stay (DE 182-1). Op. refers to Plaintiff’s Brief in Opposition to Defendants’ Motion (DE 185). 2 However, I granted Defendant’s motion with reference to Defendant BTG International, Ltd. (“BTG”), finding that Plaintiff had failed to plead detail regarding BTG’s conduct “at the level of specificity contemplated by Rule 9(b).” (DE 179 at 25.) 3 As noted in my prior opinion, the Patent Application Information Retrieval, or “PAIR,” system is an online database where the PTO is required to publish patent applications “promptly” once 18 months have elapsed since “the earliest filing date for which a benefit is sought.” (DE 179 at 15, n.14 (citing 35 U.S.C. § 122; 37 C.F.R. §1.211)). 4 The public disclosure bar requires a court to dismiss an FCA action or claim “if substantially the same allegations or transactions as alleged in the action or claim were publicly disclosed” in one of three enumerated sources: (i) “a Federal criminal, civil, or administrative hearing in which the Government or its agent is a party” (“channel (i)”); (ii) “a congressional, Government Accountability Office, or other Federal constitute a federal hearing under either channel (i) or (ii), while documents published on the PAIR system did not constitute a federal report under channel (ii). (DE 179 at 13-16.) To find otherwise, I reasoned, would ignore the evident intent behind Congress’s 2010 amendments to the FCA which limited channel (i) to federal hearings in which the Government is a party. (DE 179 at 14-16.) Defendants now urge that I certify for interlocutory appeal the questions of whether IPR proceedings qualify as “federal hearings” or whether documents on the PAIR system qualify as “federal reports” within the meaning of channel (ii) of the FCA’s public disclosure bar. (Defs. Mot. at 7.) II. DISCUSSION AND ANALYSIS Generally, a litigant may appeal only final decisions of federal district courts. Def. Distrib. v. Att'y Gen. of N.J., 972 F.3d 193, 198 (3d Cir. 2020). Interlocutory orders, like a partial dismissal, merge with the final judgment, and so an appeal encompasses review of such orders. See Verma v. 3001 Castor, Inc., 937 F.3d 221, 228 (3d Cir. 2019) (stating general merger rule). The final judgment rule, however, is “subject to limited exceptions.” Def. Distrib., 972 F.3d at 198. One such exception is for certified questions. A non-final order may be certified for appeal if the court determines that it (1) involves a “controlling question of law,” (2) for which there is “substantial ground for difference of opinion,” and (3) which may “materially advance the ultimate termination of the litigation” if appealed immediately. 28 U.S.C. § 1292(b). A “controlling question of law” is one which, if answered erroneously, would result in reversal on appeal, or which is “serious to the conduct of the litigation, either practically or legally.” Hall v. Wyeth, Inc., 2010 WL 4925258 at *1 (D.N.J. Dec. 2, 2010) (quoting Katz v. Carte Blanche Corp., 496 F.2d 747, 755 (3d Cir. 1974) (en banc)); see also Ensey v. Gov't Employers Ins. Co., No. CV 12-7669 (JEI/KMW), 2014 WL 12613400, at *2 (D.N.J. Aug. 18, 2014). A “substantial ground for

report, hearing, audit, or investigation” (“channel (ii)”); or (iii) “news media” (“channel (iii)”). 31 U.S.C. § 3730(e)(4)(A)(i)-(iii). difference of opinion” exists where “courts that have examined an issue reach ‘conflicting and contradictory opinions . . . upon the particular question of law.’” Ensey, 2014 WL 12613400 at *2 (quoting Kolbeck v. General Motors Corp., 702 F. Supp. 532, 542 (E.D. Pa. 1988)); see also Cuttic v. Crozer–Chester Med. Ctr., 806 F. Supp. 2d 796, 804–05 (E.D. Pa. 2011) (“[S]ubstantial grounds for difference of opinion exist where there is general doubt or conflicting precedent as to the correct legal standard.”). Finally, certification may materially advance a lawsuit’s ultimate termination where “the moving party shows that an immediate appeal would (1) eliminate the need for trial, (2) reduce the extent or cost of discovery, or (3) simplify the trial by eliminating complex issues.” Children First Found., Inc. v. Legreide, Civ. No. 04-2137, 2005 WL 3088334, at *10 (D.N.J. Nov. 17, 2005). Certification is, however, discretionary, and I may decline certification of a question for immediate appeal even if the three criteria are met. Ensey, 2014 WL 12613400 at *2 (citing Bachowski v. Usery, 545 F.2d 363, 368 (3d Cir. 1976); ADP, LLC v. Ultimate Software Grp., Inc., Civ. No. 16-8664, 2018 WL 1838003, at *3 (D.N.J. Apr. 17, 2018).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gillespie v. United States Steel Corp.
379 U.S. 148 (Supreme Court, 1964)
Cox Broadcasting Corp. v. Cohn
420 U.S. 469 (Supreme Court, 1975)
Bachowski v. Usery
545 F.2d 363 (Third Circuit, 1976)
Cuttic v. Crozer-Chester Medical Center
806 F. Supp. 2d 796 (E.D. Pennsylvania, 2011)
Kolbeck v. General Motors Corp.
702 F. Supp. 532 (E.D. Pennsylvania, 1989)
Priya Verma v. 3001 Castor Inc
937 F.3d 221 (Third Circuit, 2019)
Camesi v. University of Pittsburgh Medical Center
729 F.3d 239 (Third Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
SILBERSHER v. JANSSEN BIOTECH INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/silbersher-v-janssen-biotech-inc-njd-2022.